Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P H Naylor

Showing results (51-60 of 67) with videos related to

Pageof 7
Sort By:
Lancet (London, England)|April 30, 1983
Abnormal T-lymphocyte subpopulations associated with transfusion of blood-derived productsC M Kessler, R S Schulof, A L Goldstein, et al.
Cellular and Molecular Biology (Noisy-Le-Grand, France)|May 1, 1995
HIV-1 p17 synthetic peptide vaccine HGP-30: induction of immune response in human subjects and preliminary evidence of protection against HIV challenge in SCID miceP S Sarin, C A Mora, P H Naylor, et al.
Annals of Internal Medicine|February 1, 1984
Antibody to human T-cell leukemia virus membrane antigens, beta 2-microglobulin levels, and thymosin alpha 1 levels in hemophiliacs and their spousesJ K Kreiss, D N Lawrence, C K Kasper, et al.
Journal of Clinical Laboratory Analysis|January 1, 1990
Immune response and epitope mapping of a candidate HIV-1 p17 vaccine HGP30C A Boucher, W J Krone, J Goudsmit, et al.
Advances in Experimental Medicine and Biology|January 1, 1985
Thymosin in the staging and treatment of HTLV-III positive homosexuals and hemophiliacs with AIDS-related immune dysfunctionA L Goldstein, P H Naylor, R S Schulof, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|January 1, 1992
Cell-mediated immunity against HGP-30, a group-specific peptide of HIV p17 in individuals infected with the AIDS virusA Willer, A Achour, J P Mbika, et al.
The British Journal of Dermatology|August 1, 1986
Elevated thymosin alpha I levels in Brazilian pemphigus foliaceusJ T Roscoe, P H Naylor, L A Diaz, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 1, 1987
Human immunodeficiency virus contains an epitope immunoreactive with thymosin alpha 1 and the 30-amino acid synthetic p17 group-specific antigen peptide HGP-30P H Naylor, C W Naylor, M Badamchian, et al.
The American Journal of Medicine|March 1, 1986
Human T cell leukemia virus type III antibody, lymphadenopathy, and acquired immune deficiency syndrome in hemophiliac subjects. Results of a prospective studyJ K Kreiss, L W Kitchen, H E Prince, et al.
British Journal of Haematology|October 1, 1984
Inverse correlation between age related abnormalities of T-cell immunity and circulating thymosin alpha 1 levels in haemophilia AC M Kessler, R S Schulof, O Alabaster, et al.
Pageof 7

Showing results (51-60 of 67) with videos related to

Sort By:
Pageof 7
Lancet (London, England)|April 30, 1983
Abnormal T-lymphocyte subpopulations associated with transfusion of blood-derived productsC M Kessler, R S Schulof, A L Goldstein, et al.
Cellular and Molecular Biology (Noisy-Le-Grand, France)|May 1, 1995
HIV-1 p17 synthetic peptide vaccine HGP-30: induction of immune response in human subjects and preliminary evidence of protection against HIV challenge in SCID miceP S Sarin, C A Mora, P H Naylor, et al.
Annals of Internal Medicine|February 1, 1984
Antibody to human T-cell leukemia virus membrane antigens, beta 2-microglobulin levels, and thymosin alpha 1 levels in hemophiliacs and their spousesJ K Kreiss, D N Lawrence, C K Kasper, et al.
Journal of Clinical Laboratory Analysis|January 1, 1990
Immune response and epitope mapping of a candidate HIV-1 p17 vaccine HGP30C A Boucher, W J Krone, J Goudsmit, et al.
Advances in Experimental Medicine and Biology|January 1, 1985
Thymosin in the staging and treatment of HTLV-III positive homosexuals and hemophiliacs with AIDS-related immune dysfunctionA L Goldstein, P H Naylor, R S Schulof, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|January 1, 1992
Cell-mediated immunity against HGP-30, a group-specific peptide of HIV p17 in individuals infected with the AIDS virusA Willer, A Achour, J P Mbika, et al.
The British Journal of Dermatology|August 1, 1986
Elevated thymosin alpha I levels in Brazilian pemphigus foliaceusJ T Roscoe, P H Naylor, L A Diaz, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 1, 1987
Human immunodeficiency virus contains an epitope immunoreactive with thymosin alpha 1 and the 30-amino acid synthetic p17 group-specific antigen peptide HGP-30P H Naylor, C W Naylor, M Badamchian, et al.
The American Journal of Medicine|March 1, 1986
Human T cell leukemia virus type III antibody, lymphadenopathy, and acquired immune deficiency syndrome in hemophiliac subjects. Results of a prospective studyJ K Kreiss, L W Kitchen, H E Prince, et al.
British Journal of Haematology|October 1, 1984
Inverse correlation between age related abnormalities of T-cell immunity and circulating thymosin alpha 1 levels in haemophilia AC M Kessler, R S Schulof, O Alabaster, et al.
Pageof 7